Baseline Characteristics of Study Population (7)
| Characteristic | Data |
| Age (y) | |
| Median | 66 |
| Interquartile range | 60–71 |
| Male sex | 173 (84) |
| Tumor type | |
| Squamous cell carcinoma | 43 (21) |
| Adenocarcinoma | 163 (78) |
| Adenosquamous cell carcinoma | 1 (0) |
| Clinical T stage* | |
| cT1 | 1 (<1) |
| cT2 | 40 (19) |
| cT3 | 154 (74) |
| cT4 | 11 (5) |
| Missing | 1 (<1) |
| Clinical N stage | |
| N0 | 63 (30) |
| N1 | 80 (39) |
| N2 | 57 (28) |
| N3 | 6 (3) |
| Missing | 1 (<1) |
| Body mass index† | 26 ± 4.4 |
| Missing | 4 (2) |
| Lean body mass‡ | 61 ± 9.8 |
| Missing | 4 (2) |
| Glucose (mmol/L) | 5.9 ± 1.3 |
| Missing | 6 (3) |
| Injected 18F-FDG dose (MBq) | 212 ± 64.3 |
| Missing | 2 (1) |
| Interval between injection and scanning (min) | 61.0 ± 9.1 |
| Missing | 5 (2) |